Sign in
CompletedNo phase

Arrhythmia in Hemodialysis Patients

Key facts

Who runs it
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
18 people enrolled
Started
17 Oct 2019
Ended
24 Jun 2026
Type of study
Interventional
Treatments tested
  • Reveal LINQ insertable cardiac monitoring system
Record updated
26 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • No significant residual renal function (<250ml of urine per day)
  • Must be on hemodialysis for at least 3 months
  • Age ≥18 years
  • Able/willing to provide informed consent

Who cannot take part

  • Prior diagnosis of chronic arrhythmia and/or are on anti-arrhythmic drugs
  • Presence of a pacemaker and implantable cardioverter defibrillator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients receiving dialysis for kidney failure suffer from very high rates of sudden cardiac death due to abnormal heart rhythms and perfusion defects associated with HD treatment. It has previously been recognized that patients suffer heart injury during the dialysis procedure which may be an important factor for investigation. The study uses a simple implantable device that can monitor heart rhythms over time to gather information on the type of abnormal rhythms that occur in dialysis patients. This information will be combined with ultrasound and x-ray scans of the heart that will also be collected. The goal is to understand the relationship between the abnormal rhythms and injury to the heart during dialysis and what causes these injuries. The information gathered in this study will be used to compare the accuracy of an in house personalized computational model to predict potential cardiac injuries when patients undergo HD treatment.

The group in the trial

  • Reveal LINQ insertable cardiac monitoring systemTreatment being tested

    In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigation of Electrophysiological Substrate of Arrhythmia in Hemodialysis Patients
Record updated
26 June 2026